What are Utah Medical Products's total assets?

Utah Medical Products (UTMD) holds $124.4M in total assets, up 1.5% year over year.

How much debt does Utah Medical Products have?

Utah Medical Products carries $210.0K in total debt against $120.4M of shareholders' equity, a debt-to-equity ratio of 0.00.

How much cash does Utah Medical Products have?

Utah Medical Products holds $87.4M in cash and equivalents.

Can Utah Medical Products cover its short-term obligations?

Its current ratio is 28.64 — current assets exceed current liabilities.

Where does Utah Medical Products's balance sheet data come from?

Every line is extracted from Utah Medical Products's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Utah Medical Products UTMD Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$87.41M+4.9%	$85.76M+3.4%	$84.27M-4.7%	$82.18M-7.9%	$83.33M-11.2%
Inventories	$8.72M+0.9%	$7.94M-10.0%	$8.12M-10.9%	$8.23M-9.1%	$8.65M-6.4%
Raw materials	$5.31M-3.4%	$5.09M-7.3%	$5.29M-16.2%	$5.86M-6.9%	$5.5M-12.7%
Work in process	$1.85M+19.7%	$1.63M+15.1%	$1.61M+11.5%	$1.41M-2.0%	$1.54M+18.6%
Finished goods	$1.56M-2.6%	$1.22M-36.1%	$1.22M-9.7%	$971K-27.2%	$1.6M-2.0%
Prepaid expenses and other current assets	$614K+27.4%	$529K+18.1%	$422K+11.9%	$331K-12.2%	$482K-5.5%
Total current assets	$100.38M+4.1%	$97.74M+1.5%	$96.53M-5.0%	$94.38M-7.8%	$96.4M-10.0%
Property and equipment, net	$9.72M-2.3%	$9.91M+1.5%	$10M-4.0%	$10.26M+0.6%	$9.95M-3.1%
Land	——	$1.7M+5.8%	——	——	——
Buildings and improvements	——	$14.39M+6.2%	——	——	——
Machinery and equipment	——	$19.06M+2.8%	——	——	——
Construction in progress	——	$110K+479%	——	——	——
Accumulated depreciation	$54.93M+5.1%	$25.34M+5.9%	$54.56M+4.3%	$54.66M+9.0%	$52.25M+5.2%
Goodwill	$13.92M+1.1%	$14.05M+3.5%	$14.05M+0.2%	$14.19M+4.1%	$13.77M+1.0%
Intangible assets, net	$364K-84.9%	$840K-70.7%	$1.39M-61.2%	$1.98M-49.0%	$2.41M-45.2%
Deferred tax assets	$294K-23.6%	$337K-69.4%	$223K-22.0%	$370K+77.9%	$385K+50.4%
Total assets	$124.38M+1.5%	$122.54M0.0%	$121.98M-6.0%	$120.8M-7.1%	$122.52M-9.5%
Accounts payable	$1.19M+30.6%	$911K+30.9%	$768K-23.1%	$737K-11.6%	$914K-8.4%
Accrued expenses	$2.31M-32.2%	$1.69M+47.0%	$2.24M-7.9%	$1.52M-51.1%	$3.41M-23.8%
Total current liabilities	$3.51M-18.9%	$2.6M-30.8%	$3.01M-12.3%	$2.25M-42.8%	$4.32M-21.0%
Long-term debt	$210K—	$0-100%	$241K—	$0—	$0—
Total liabilities	$4.01M-26.7%	$3.27M-35.9%	$3.72M-32.3%	$3.27M-45.3%	$5.47M-28.9%
Common stock	50M0.0%	50M0.0%	50M0.0%	50M0.0%	50M0.0%
Additional paid-in capital	$0—	$0—	$0—	$0—	$0—
Retained earnings	$130.26M+1.6%	$128.65M-0.5%	$127.96M-4.5%	$126.86M-6.3%	$128.2M-7.8%
Accumulated other comprehensive income (loss)	-$9.92M+11.4%	-$9.42M+20.9%	-$9.74M+1.5%	-$9.36M+17.3%	-$11.19M+0.9%
Total stockholders' equity	$120.37M+2.8%	$119.27M+1.6%	$118.25M-4.8%	$117.53M-5.3%	$117.05M-8.4%
Total liabilities and stockholders' equity	$124.38M+1.5%	$122.54M0.0%	$121.98M-6.0%	$120.8M-7.1%	$122.52M-9.5%
Commitments and contingencies	——	$0—	——	——	——
Allowance for Doubtful Accounts	——	$515K+260%	——	——	——
Allowance for Doubtful Accounts Receivable (Current)	——	$515K+260%	——	——	——
Contract Assets, Net	——	$254K-5.9%	——	——	——
Finished goods	$1.56M-2.6%	$1.22M-36.1%	$1.22M-9.7%	$971K-27.2%	$1.6M-2.0%
Other current assets	$614K+27.4%	$529K+18.1%	$422K+11.9%	$331K-12.2%	$482K-5.5%
Other Inventory, Net	——	$254K-5.9%	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	$9K-18.2%	——	——	——
Finite Lived Intangible Assets - Gross	$55.3M+1.2%	$55.94M+4.0%	$55.95M+0.1%	$56.64M+4.8%	$54.65M+1.1%
Intangible assets — net	——	$840K-70.7%	——	——	——
Other intangible assets—net	$364K-84.9%	$840K-70.7%	$1.39M-61.2%	$1.98M-49.0%	$2.41M-45.2%
Machinery and equipment	——	$19.06M+2.8%	——	——	——
Other Finite-Lived Intangible Assets, Gross	——	$21M0.0%	——	——	——
Property, plant and equipment at cost	——	$35.25M+4.6%	——	——	——
Accrued Litigation	——	$68K-38.7%	——	——	——
Accrued Manufacturing Costs	——	$853K-25.7%	——	——	——
Other Commercial Liabilities	$2.31M-32.2%	$1.69M-44.9%	$2.24M-7.9%	$1.52M-51.1%	$3.41M-23.8%
Accrued Liabilities, Current	$2.31M-32.2%	$1.69M-44.9%	$2.24M-7.9%	$1.52M-51.1%	$3.41M-23.8%
Compensation and benefits	——	$853K-25.7%	——	——	——
Long-Term Debt and Finance Lease Obligations	$210K-21.9%	$225K-20.2%	——	——	$269K—
Accrued litigation	——	$68K-38.7%	——	——	——
Total debt	$210K—	$286K-49.3%	$241K-19.4%	$256K-6.9%	——
Common Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common Stock Shares Issued	3.2M-3.0%	3.2M-4.5%	3.2M-6.9%	3.2M-8.1%	3.3M-8.6%
Common Stock Shares Outstanding	——	$0—	——	——	——
Additional paid-in capital	$0—	$0—	$0—	$0—	$0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$32K-3.0%	$32K-3.0%	$32K-5.9%	$32K-8.6%	$33K-8.3%
Number of Exercisable Options	——	65K+25.0%	——	——	——
Share-Based Payment Award Options Outstanding - Number	——	121K+23.5%	——	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	$1.01M+12.9%	——	——	——
Shares Reserved for Future Issuance Under Stock Plans	——	275K0.0%	——	——	——
Cumulative Cost Basis	——	$35.25M+4.6%	——	——	——
Accrued Income Taxes Payable Receivable	——	-$909K-494%	——	——	——
Accrued Interest And Other	——	$2K+200%	——	——	——
Accumulated Other Comprehensive Income Loss Before Tax1	-$9.92M+11.4%	-$9.42M+20.9%	-$9.74M+1.5%	-$9.36M+17.3%	-$11.19M+0.9%
Allowance for doubtful accounts	——	$515K+260%	——	——	——
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	$50M0.0%	$50M0.0%	$50M0.0%	$50M0.0%	$50M0.0%
Common stock, shares issued (in shares)	$3.18M-3.0%	$3.19M-4.5%	$3.2M-6.9%	$3.22M-8.1%	$3.28M-8.6%
Common Stock, Shares, Outstanding	$3.18M-3.0%	$3.19M-4.5%	$3.2M-6.9%	$3.22M-8.1%	$3.28M-8.6%
Construction work in progress	——	$110K+479%	——	——	——
Deferred income taxes	$294K-23.6%	$337K-28.1%	$223K-22.0%	$370K+77.9%	$385K+50.4%
Accrued expenses	——	$43K-14.0%	——	——	——
Deferred Tax Liabilities, Net	——	$488K-55.7%	——	——	——
Deferred Tax Liabilities Depreciation And Amortization	——	$861K-40.7%	——	——	——
Federal and state intangible assets	$0-100%	$114K-81.1%	$248K-68.2%	$389K-54.8%	$494K-49.9%
Employee Service Share Based Compensation Nonvested Awards Compensation Cost Not Yet Recognized To Be Recognized Over The Next Four Years	——	$572K+100,251%	——	——	——
Unrecognized compensation cost related to non-vested awards	——	$1.01M+12.9%	——	——	——
Employee Service Share Based Compensation Nonvested Awards Compensation Cost Not Yet Recognized To Be Recognized Over The Next Twelve Months	——	$442K+34.3%	——	——	——
Finite-Lived Customer Relationships, Gross	——	$9.61M+7.4%	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$54.93M+5.1%	$55.1M+8.2%	$54.56M+4.3%	$54.66M+9.0%	$52.25M+5.2%
2028	——	$12K-97.2%	——	——	——
2030	——	$9K-18.2%	——	——	——
2031	——	$9K-10.0%	——	——	——
2027	——	$433K-77.6%	——	——	——
2029	——	$10K-28.6%	——	——	——
Gross Carrying Amount	$55.3M+1.2%	$55.94M+4.0%	$55.95M+0.1%	$56.64M+4.8%	$54.65M+1.1%
Finite Lived Noncompete Agreements Gross	——	$134K+7.2%	——	——	——
Finite-Lived Patents, Gross	——	$2.22M+0.5%	——	——	——
Finite Lived Regulatory Approvals And Product Certifications Gross	——	$12.82M+7.4%	——	——	——
Finite Lived Trademarks Gross	——	$9.87M+7.2%	——	——	——
Foreign Currency Exchange Rate Translation AU Dto USD	——	666,800%+666,738%	——	——	——
Foreign Currency Exchange Rate Translation GB Pto USD	——	134.5%+9.2%	——	——	——
Raw materials	$5.31M-3.4%	$5.09M-7.3%	$5.29M-16.2%	$5.86M-6.9%	$5.5M-12.7%
Estimated litigation liability	——	$68K-38.7%	——	——	——
Long Lived Assets In Australia	——	$296K+2.1%	——	——	——
Long Lived Assets In Canada	——	$531K+1.5%	——	——	——
Long Lived Assets In England	——	$9.98M-12.8%	——	——	——
Long Lived Assets In Ireland	——	$3.02M+6.9%	——	——	——
Long Lived Assets In The United States	——	$10.97M-1.4%	——	——	——
Long-Term Debt and Lease Obligation	$210K-21.9%	$225K-20.2%	——	——	$269K—
Other accrued liabilities	——	$1.68M-14.3%	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	$65K+25.0%	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	——	$121K+23.5%	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	——	$0—	——	——	——
Shares reserved for awards to employees and outside directors (in shares)	——	$275K0.0%	——	——	——
Purchase Obligation	——	$4.34M+15.8%	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Utah Medical Products.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Utah Medical Products's total assets?: Utah Medical Products (UTMD) holds $124.4M in total assets, up 1.5% year over year.
How much debt does Utah Medical Products have?: Utah Medical Products carries $210.0K in total debt against $120.4M of shareholders' equity, a debt-to-equity ratio of 0.00.
How much cash does Utah Medical Products have?: Utah Medical Products holds $87.4M in cash and equivalents.
Can Utah Medical Products cover its short-term obligations?: Its current ratio is 28.64 — current assets exceed current liabilities.
Where does Utah Medical Products's balance sheet data come from?: Every line is extracted from Utah Medical Products's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.